Fig. 5

Differential Impact of BET inhibitor Monotherapy and Atezolizumab Combination Therapy on Immune Effector Pathways: Heatmaps illustrate the contrasting effects of atezolizumab combination therapy and BET inhibitor monotherapy on immune effector pathways within tumor tissues, based on RNA sequencing data. A. Enrichment scores for key immune pathways [34]. Green indicates significant upregulation in combination therapy, suggesting enhanced immune activity. Purple marks downregulation in BETi monotherapy, implying reduced immune response. B. Gene expression changes related to CD8 T effector, immune checkpoint, and antigen processing machinery pathways are highlighted. Red represents upregulated genes, reflecting pathway activation, while blue indicates downregulated genes, signifying pathway suppression. Significant changes are marked with asterisk.